Drägerwerk AG & Co. KGaA (DRW8.DE) • XETRA
Unlock comprehensive alternative data signals to make better investment decisions

Track website visits, page views, unique visitors, and engagement metrics over time to gauge online interest and brand strength.

Monitor Twitter follower growth, engagement rates, and social media presence to understand brand reach and community sentiment.

Analyze TikTok follower trends and viral content performance to measure youth demographic appeal and cultural relevance.

Track Facebook page likes, comments, shares, and post engagement to assess community interaction and brand loyalty.

Monitor Instagram follower growth, engagement rates, and visual content performance across demographics.

Track YouTube channel growth, video views, and subscriber engagement to measure content marketing effectiveness.

Monitor LinkedIn company page followers and professional network growth to assess B2B brand strength and talent attraction.

Track open job positions and hiring trends as a leading indicator of company expansion, contraction, or strategic shifts.

Monitor employee headcount changes on LinkedIn to gauge organizational growth, restructuring, or cost-cutting measures.

Analyze sentiment scores from Reddit discussions to understand retail investor mood and potential price momentum.

Track daily news mentions across major publications to measure media attention, PR effectiveness, and market awareness.

View key financial metrics including Revenue, Net Income, EPS, Free Cash Flow, EBITDA, and Total Assets. Access 2-year quarterly charts for Revenue & Income and Free Cash Flow trends.

Analyze technical indicators including 50-day Simple Moving Average (SMA) with price overlay and Relative Strength Index (RSI) charts.
TrendEdge provides tools and data for research and educational purposes only and does not provide investment advice or personal recommendations.
You don't hold DRW8.DE in your mock portfolio yet.
With EPS of €8.14 and a PE ratio of 8.60, Drägerwerk is generating solid earnings relative to its current valuation, implying a low earnings multiple versus many peers in medical/industrial equipment. While detailed revenue and margin data are not provided here, the strong EPS level suggests the company is currently profitable and likely operating with reasonable margins. Overall, the earnings profile looks supportive of the stock at current levels, assuming no imminent deterioration in fundamentals.
The stock trades at €70.00, modestly above its 200‑day moving average of €65.14, indicating a generally positive longer‑term trend. However, the 4.6% decline over the last month shows near‑term weakness and possible consolidation after a prior advance. Overall, price action is mixed: structurally constructive above the 200‑day average, but with short‑term pressure that tempers a clearly bullish stance.
Alternative data points for Drägerwerk show healthy digital engagement and operational activity. Web traffic of roughly 486,000 monthly visitors and about 10,000 mobile app downloads per day indicate strong and ongoing user interaction with the company’s products and services. The modest growth in job openings and generally stable to rising social media presence suggest a company that is investing in growth and maintaining brand visibility, supporting a positive forward‑looking view.
Drägerwerk AG & Co. KGaA shows a combination of solid earnings, a low valuation multiple, and constructive alternative data, but this is offset by recent short‑term stock price weakness. The shares trade above their 200‑day moving average, suggesting the longer‑term trend remains intact, yet the 4.6% monthly decline indicates some near‑term caution among investors. Taken together, the evidence points to a neutral overall stance with a mildly positive bias contingent on earnings stability and confirmation from future results.
Our AI Score rates companies on a scale from 0 to 10, based on alternative data points such as web traffic, app downloads, and job postings — combined with financial health indicators and technical signals.
Upgrade to see the full Evidence Stack
What Changed, Why Now, and Risk Flags — available on the Investor plan and above
Get Started